- Home
- OBIO vs CLLS Comparison
OBIO vs CLLS Comparison
Compare OBIO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- CLLS
- Stock Information
- Founded
- OBIO 2017
- CLLS 1999
- Country
- OBIO United States
- CLLS France
- Employees
- OBIO N/A
- CLLS N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- CLLS Health Care
- Exchange
- OBIO Nasdaq
- CLLS Nasdaq
- Market Cap
- OBIO 124.9M
- CLLS 143.4M
- IPO Year
- OBIO N/A
- CLLS 2007
- Fundamental
- Price
- OBIO $3.01
- CLLS $1.47
- Analyst Decision
- OBIO Strong Buy
- CLLS Buy
- Analyst Count
- OBIO 5
- CLLS 2
- Target Price
- OBIO $14.20
- CLLS $7.00
- AVG Volume (30 Days)
- OBIO 236.8K
- CLLS 53.4K
- Earning Date
- OBIO 08-11-2025
- CLLS 08-05-2025
- Dividend Yield
- OBIO N/A
- CLLS N/A
- EPS Growth
- OBIO N/A
- CLLS N/A
- EPS
- OBIO N/A
- CLLS N/A
- Revenue
- OBIO $2,886,000.00
- CLLS $54,747,000.00
- Revenue This Year
- OBIO $20.47
- CLLS $48.52
- Revenue Next Year
- OBIO $11.45
- CLLS $5.17
- P/E Ratio
- OBIO N/A
- CLLS N/A
- Revenue Growth
- OBIO 30.23
- CLLS 351.26
- 52 Week Low
- OBIO $2.37
- CLLS $1.10
- 52 Week High
- OBIO $8.87
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- OBIO 47.82
- CLLS 53.84
- Support Level
- OBIO $2.91
- CLLS $1.33
- Resistance Level
- OBIO $3.48
- CLLS $1.46
- Average True Range (ATR)
- OBIO 0.26
- CLLS 0.07
- MACD
- OBIO -0.01
- CLLS 0.00
- Stochastic Oscillator
- OBIO 28.78
- CLLS 64.13
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.